Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Alebund Pty Ltd
- Target Recruit Count
- 32
- Registration Number
- NCT06100627
- Locations
- 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: Placebo 50 μgDrug: AP303 50 μgDrug: AP303 150 μgDrug: Placebo 150 μgDrug: AP303 300 μgDrug: Placebo 300 μgDrug: Placebo 600 μgDrug: AP303 600 μg
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Alebund Pty Ltd
- Target Recruit Count
- 62
- Registration Number
- NCT05503693
- Locations
- 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
News
No news found